Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social communication and interaction, and restricted, repetitive patterns of behaviour. Approximately 1 in 70 children are diagnosed with ASD at an average age of 4 years with early therapeutic intervention shown to lessen the burden of ASD to the children and their families. A blood-based biomarker is crucially-needed for ASD as it would facilitate early intervention with behavioral therapies. Now, a study from researchers at UT Southwestern Medical Center identifies a blood-based biomarker that may aid in earlier diagnosis of children with ASD. The team state that their findings identify a peptoid that can distinguish between ASD and normal male serum based upon its ability to bind to an antibody. The opensource study is published in the journal Scientific Reports.
Previous studies show that the immune system has been linked with ASD on numerous occasions. Abnormalities in both serum antibody concentrations and T cells have been reported for ASD compared to typically-developing children. Immunological anomalies in children with ASD include altered cytokine profiles, decreased immunoglobulin levels, altered cellular immunity, and neuroinflammation. Autoimmunity has also been described for autism with several studies reporting circulating autoantibodies to neural antigens. The current study sought to examine the immune system to search for antibodies in the blood that may be related to ASD.
The current study shows that boys with ASD have significantly reduced levels of a serum IgG1 antibody. Results show that analyzing 25 peptoid compounds that bind to IgG1, zeroes in on ASD1, which is 66% accurate in diagnosing ASD. Data findings show that when combined with thyroid stimulating hormone level measurements, the ASD1-binding biomarker was 73% accurate at diagnosis.
The team surmise they have identified a blood biomarker that distinguishes the majority of ASD study participants from a control group of similar age range. They go on to add that the biomarker was significantly correlated with the level of communication impairment, suggesting that the blood test may give insight into ASD severity. For the future, the researchers state that more testing, including analysis of blood samples from girls with ASD, is needed to further validate the findings.
Source: UT Southwestern Medical Center
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.